Study or Subgroup	Placebo/MTX Events	Total	JAKI+MTX Events	Total	Weight	Risk Ratio M-H, Random, 95% CI
8.3.1 Baricitinib 1mg + MTX						
Tanaka 2016	0	11	0	6		Not estimable
Subtotal (95% CI)		**11**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
8.3.2 Baricitinib 2mg + MTX						
Tanaka 2016	0	11	0	6		Not estimable
Subtotal (95% CI)		**11**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
8.3.3 Baricitinib 4mg + MTX						
Fleischman 2017	1	210	4	215	43.8%	0.26 [0.03, 2.27]
Li 2020	0	57	0	62		Not estimable
Tanaka 2016	0	11	0	6		Not estimable
Taylor 2017	3	198	3	431	56.2%	2.18 [0.44, 10.69]
Subtotal (95% CI)		**476**		**714**	**100.0%**	**0.85 [0.10, 7.02]**
Total events	4		7			
Heterogeneity: $Tau^2 = 1.40$; $Chi^2 = 2.48$, df = 1 (P = 0.12); $I^2 = 60\%$						
Test for overall effect: Z = 0.15 (P = 0.88)						
8.3.4 Baricitinib 8mg + MTX						
Tanaka 2016	0	11	0	6		Not estimable
Subtotal (95% CI)		**11**		**6**		**Not estimable**
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
Total (95% CI)		**509**		**732**	**100.0%**	**0.85 [0.10, 7.02]**
Total events	4		7			
Heterogeneity: $Tau^2 = 1.40$; $Chi^2 = 2.48$, df = 1 (P = 0.12); $I^2 = 60\%$						
Test for overall effect: Z = 0.15 (P = 0.88)						
Test for subgroup differences: Not applicable